Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | LTX-315 |
Trade Name | |
Synonyms | Ruxotemitide |
Drug Descriptions |
Ruxotemitide (LTX-315) is a 9-mer oncolytic peptide that induces release of danger-associated molecular pattern molecules (DAMPs), and may increase anti-tumor immune response and decrease tumor growth (PMID: 26982623, PMID: 30670061, PMID: 32258289). |
DrugClasses | |
CAS Registry Number | 1345407-05-7 |
NCIT ID | C90547 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
LTX-315 | LTX-315 | 0 | 1 |
LTX-315 + Pegylated liposomal doxorubicin | LTX-315 Pegylated liposomal doxorubicin | 0 | 0 |
LTX-315 + Pembrolizumab | LTX-315 Pembrolizumab | 0 | 1 |